|
1) Chu JW, Matthias DF, Belnoff J, et al. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU486). J Clin Endocrinol Metab. 2001; 86: 3568-73
|
|
|
|
2) Walker BR. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy parti-tioning. Proc Nutr Soc. 2007; 66: 1-8
|
|
|
|
|
|
3) Morton NM, Seckl JR. 11beta-hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res. 2008; 36: 146-64
|
|
|
|
|
|
4) Hu X, Funder JW. The evolution of mineralo-corticoid receptors. Mol Endocrinol. 2006; 20: 1471-8
|
|
|
|
|
|
5) Caprio M, Feve B, Claes A, et al. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J. 2007; 21: 2185-94
|
|
|
|
|
|
6) Kannisto K, Pietilainen KH, Ehrenborg E, et al. Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab. 2004; 89: 4414-21
|
|
|
|
|
|
7) Hale C, Wang M. Development of 11β-HSD1 inhibitors for the treatment of type 2 diabetes. Mini Rev Med Chem. 2008; 8: 702-10
|
|
|
|
|
|
8) Matsuzawa Y. Therapy Insight: aipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2006; 3: 35-42
|
|
|
|
|
|
9) Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes. 2000; 49: 883-8
|
|
|
|
|
|
10) Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001; 294: 2166-70
|
|
|
|
|
|
11) Masuzaki H, Yamamoto H, Kenyon CJ, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest. 2003; 112: 83-90
|
|
|
|
|
|
12) Morton NM, Paterson J, Masuzaki H, et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type-1 deficient mice. Diabetes. 2004; 53: 931-8
|
|
|
|
|
|
13) Morton NM, Holmes MC, Fievet C, et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem. 2001; 44: 41293-301
|
|
|
|
|
|
14) Kershaw EE, Morton NM, Dhillon H, et al. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes. 2005; 54: 1023-31
|
|
|
|
|
|
15) Paterson JM, Morton NM, Fievet C, et al. Metabolic syndrome without obesity: Hepatic overexpression of 11β-hydroxysteroid dehydro-genase type 1 in transgenic mice. Proc Natl Acad Sci U S A. 2004; 101: 7088-93
|
|
|
|
|
|
16) Bujalska IJ, Hewitt KN, Hauton D, et al. Lack of hexose-6-phosphate dehydrogenase impairs lipid mobilization from mouse adipose tissue. Endocrinology. 2008; 149: 2584-91
|
|
|
|
|
|
17) Tomlinson JW, Stewart PM. Mechanisms of disease: Selective inhibition of 11beta-hydroxy-steroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome. Nat Clin Pract Endocrinol Metab. 2005; 1: 92-9
|
|
|
|
|
|
18) Kuo LE, Kitlinska JB, Tilan JU, et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med. 2007; 13: 803-11
|
|
|
|
|
|
19) Hermanowski-Vosatka A, Balkovec JM, Cheng K, et al. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of athero-sclerosis in mice. J Exp Med. 2005; 202: 517-27
|
|
|
|
|
|
20) Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov. 2006; 5: 295-309
|
|
|
|
|
|
21) Ishii T, Masuzaki H, Tanaka T, et al. Augmentation of 11beta-hydroxysteroid dehydrogenase type 1 in LPS-activated J'774. 1 macrophages--role of 11beta-HSD1 in pro-inflammatory properties in macrophages. FEBS Lett. 2007; 581: 349-54
|
|
|
|
|
|
22) Arai N, Masuzaki H, Tanaka T, et al. Ceramide and adenosine 5's-monophospate-activated protein kinase are two novel regulators of 11beta-hydroxysteroid dehydrogenase type 1 expression and activity in cultutured preadipo-cytes. Endocrinology. 2007; 148: 5268- 77
|
|
|
|
|
|
23) De Sousa Peixoto RA, Turban S, Battle JH, et al. Preadipocyte 11beta-hydroxysteroid dehydro-genase type 1 is a keto-reductase and conributes to diet-induced visceral obesity in vivo. Endocrinology. 2008; 149: 1861-8
|
|
|
|
|
|
24) Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004; 141: 764-70
|
|
|
|
|
|
25) Chapman KE, Seckl JR. 11beta-HSD1, inflammation, metabolic disease and age-related cognitive (dys)function. Neurochem Res. 2008; 33: 624-36
|
|
|
|
|
|
26) Sandeep TC, Yau JL, MacLullich AM, et al. 11beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetes. Proc Natl Acad Sci U S A. 2004; 101: 6734-9
|
|
|
|
|
|
27) Stranahan AM, Arumugam TV, Cutler RG, et al. Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat Neurosci. 2008; 11: 309-17
|
|
|
|
|
|
28) Meaney MJ, Szyf M, Seckl JR. Epigenetic mechanisms of perinatal programming of hypothalamic-pituitary-arenal function and health. Trends Mol Med. 2007; 13: 269-77
|
|
|
|
|